Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Longeveron

NASDAQ: LGVN ↗$2.49 USD~$0.05B MCAP
#Cardiovascular#Neuroscience#Regenerative Medicine

Clinical-stage cell therapy company developing laromestrocel (Lomecel-B), an allogeneic mesenchymal stem cell therapy, for hypoplastic left heart syndrome, Alzheimer's disease and aging frailty.

Company Info

Sector:Cell Therapy / Regenerative Medicine
Headquarters:Miami, Florida, USA
Founded:2014
Website:longeveron.com/

Upcoming Milestones & Key Dates

2026-Q4
Data Readout

Additional data from the ELPIS-II cardiac program

Clinical Development Pipeline

laromestrocel (Lomecel-B)

Target: Mesenchymal stem cell therapy
Hypoplastic left heart syndrome
Preclinical
Phase 1
Phase 2
Phase 3
Approved

laromestrocel (Lomecel-B)

Target: Mesenchymal stem cell therapy
Alzheimer's disease
Preclinical
Phase 1
Phase 2
Phase 3
Approved

laromestrocel (Lomecel-B)

Target: Mesenchymal stem cell therapy
Aging frailty
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Careers & Job Openings

See all open roles

Careers
Miami, FL
Apply Now →